ERBB2 and gastric cancer: As a targeted drug for gastric cancer, trastuzumab could stop the formation of ERBB2 homologous dimers, prevent the activation of the signaling pathways of cell proliferation, and kill tumor cells through antibody-dependent cellular cytotoxicity [94].